Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination
Posted On: 2020-12-29 01:49:21 (Time Zone: Arizona, USA)
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.
Glenmark Logo
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India ANI | Updated: Dec 29, 2020 16:38 IST
Mumbai (Maharashtra) [India], December 29 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.
Global Mental Disorder Treatment Market to Surpass US$ 75 7 Billion by 2027, Says Coherent Market Insights (CMI) – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Related Market Intelligence Report:
Mental Health Software Market, by Deployment mode(On-premise and Subscription (Cloud-based)), by Mode of Access(Desktops/Laptops and Tablets/Smartphones), by Function(Telehealth, Payroll, Revenue Cycle Management (RCM),Ledger, Business Intelligence, Electronic Health Record (EHR) and Clinical Decision Support), by Application(Commercial, Hospitals and Clinics, Others(Psychiatrists, Social Workers, Psychologists, Counsellors, Nurse Practitioners, Group Therapists) and Residential) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Depression Therapeutics Market, Drug Type (Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants and Atypical Antidepressants), Antipsychotics and Others), by Indication (Major Depressive Disord
Volume Decline Muted Pharmaceutical Market Growth In November Volume Decline Muted Pharmaceutical Market Growth In November The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products
Pharmaceutical market reported Rs 128.3 billion total sales in November 2020
The sluggish growth of the Indian pharmaceutical market during November 2020 was largely led by a volume decline, while the growth in prices and new products remained healthy. The decline in volume can be attributed to the lower sales of the acute therapy products on account of a higher base in the corresponding month last year. According to a recent research report released by India Ratings and Research (Ind-Ra), the pharmaceutical market reported Rs 128.3 billion total sales in November 2020. On a monthly average total, for the past 12 months basis, the growth was 3.0 per cent for the same month.